uniQure (NASDAQ:QURE – Get Rating) has been assigned a consensus recommendation of “Buy” from the fourteen ratings firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among analysts […]
Equities analysts forecast that uniQure (NASDAQ:QURE – Get Rating) will post $37.45 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for uniQure’s earnings, with estimates ranging from $17.90 million to $57.00 million. uniQure posted sales of $463.87 million in the same quarter last year, which would indicate […]
uniQure (NASDAQ:QURE – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday, Zacks.com reports. According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, […]
StockNews.com initiated coverage on shares of uniQure (NASDAQ:QURE – Get Rating) in a report published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock. Several other equities research analysts also recently weighed in on the stock. Raymond James downgraded shares of uniQure from a strong-buy rating to an outperform rating and […]
uniQure (NASDAQ:QURE – Get Rating)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a report released on Tuesday, Zacks.com reports. A number of other analysts have also weighed in on the stock. UBS Group raised shares of uniQure from a “neutral” rating to a “buy” rating and set a $40.00 […]